250 related articles for article (PubMed ID: 20376625)
21. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
22. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonates or prostacyclin in the treatment of bone-marrow oedema syndrome of the knee and foot.
Baier C; Schaumburger J; Götz J; Heers G; Schmidt T; Grifka J; Beckmann J
Rheumatol Int; 2013 Jun; 33(6):1397-402. PubMed ID: 23143557
[TBL] [Abstract][Full Text] [Related]
24. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
[TBL] [Abstract][Full Text] [Related]
25. The use of bisphosphonate in the treatment of avascular necrosis: a systematic review.
Cardozo JB; Andrade DM; Santiago MB
Clin Rheumatol; 2008 Jun; 27(6):685-8. PubMed ID: 18270760
[TBL] [Abstract][Full Text] [Related]
26. Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.
Vieillard MH; Maes JM; Penel G; Facon T; Magro L; Bonneterre J; Cortet B
Joint Bone Spine; 2008 Jan; 75(1):34-40. PubMed ID: 17981488
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
28. Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL).
Kotecha RS; Powers N; Lee SJ; Murray KJ; Carter T; Cole C
Pediatr Blood Cancer; 2010 Jul; 54(7):934-40. PubMed ID: 20127847
[TBL] [Abstract][Full Text] [Related]
29. Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared.
Bettica P; Bevilacqua M; Vago T; Masino M; Cucinotta E; Norbiato G
J Clin Endocrinol Metab; 1997 Sep; 82(9):3034-9. PubMed ID: 9284739
[TBL] [Abstract][Full Text] [Related]
30. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
[TBL] [Abstract][Full Text] [Related]
31. The relation of oral bisphosphonates to bone marrow lesion volume among women with osteoarthritis.
Ballal P; Sury M; Lu N; Duryea J; Zhang Y; Ratzlaff C; Neogi T
Osteoarthritis Cartilage; 2020 Oct; 28(10):1325-1329. PubMed ID: 32768598
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia.
Leblicq C; Laverdière C; Décarie JC; Delisle JF; Isler MH; Moghrabi A; Chabot G; Alos N
Pediatr Blood Cancer; 2013 May; 60(5):741-7. PubMed ID: 23002054
[TBL] [Abstract][Full Text] [Related]
33. An open-label, prospective, observational study of the efficacy of bisphosphonate therapy for painful osteoid osteoma.
Bousson V; Leturcq T; Ea HK; Hauger O; Mehsen-Cetre N; Hamzé B; Parlier-Cuau C; Laredo JD; Schaeverbeke T; Orcel P
Eur Radiol; 2018 Feb; 28(2):478-486. PubMed ID: 28884296
[TBL] [Abstract][Full Text] [Related]
34. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine.
Gertz BJ; Shao P; Hanson DA; Quan H; Harris ST; Genant HK; Chesnut CH; Eyre DR
J Bone Miner Res; 1994 Feb; 9(2):135-42. PubMed ID: 8140926
[TBL] [Abstract][Full Text] [Related]
35. Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates.
Kim JW; Kong KA; Kim SJ; Choi SK; Cha IH; Kim MR
Bone; 2013 Nov; 57(1):201-5. PubMed ID: 23954759
[TBL] [Abstract][Full Text] [Related]
36. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
Marx RE; Cillo JE; Ulloa JJ
J Oral Maxillofac Surg; 2007 Dec; 65(12):2397-410. PubMed ID: 18022461
[TBL] [Abstract][Full Text] [Related]
37. Rationale for prostaglandin I2 in bone marrow oedema--from theory to application.
Jäger M; Tillmann FP; Thornhill TS; Mahmoudi M; Blondin D; Hetzel GR; Zilkens C; Krauspe R
Arthritis Res Ther; 2008; 10(5):R120. PubMed ID: 18834533
[TBL] [Abstract][Full Text] [Related]
38. Response to alendronate in osteoporotic women previously treated with pamidronate.
Peretz A; Siderova V; Body JJ; Dumon JC; Rozenberg S; Fellemans C; Fuss M; Bergmann P;
Maturitas; 2003 Feb; 44(2):111-5. PubMed ID: 12590006
[TBL] [Abstract][Full Text] [Related]
39. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
Wutzl A; Eisenmenger G; Hoffmann M; Czerny C; Moser D; Pietschmann P; Ewers R; Baumann A
Wien Klin Wochenschr; 2006 Aug; 118(15-16):473-8. PubMed ID: 16957978
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
Grewal VS; Fayans EP
Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
